Search

everythinglearnresearchcommunity

for

Search:↓

Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Serum triglyceride levels are not linked to prostate cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

The document suggests more research is needed to understand the link between baldness and prostate cancer.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

African American men with prostate cancer have more androgen receptor mutations, which may lead to more aggressive cancer compared to Caucasian American men.

E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.

A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Vertex pattern hair loss linked to higher prostate cancer risk.

Late puberty may slightly lower prostate cancer risk, baldness is not linked to overall risk but less so with aggressive types, ibuprofen use may increase risk, and vitamins show no effect on risk.

Men with baldness at the front and top of their head at age 45 may have a higher risk of aggressive prostate cancer.

Male pattern baldness might have evolved to help protect against prostate cancer by increasing UV radiation on the scalp.

Men with melanoma have a higher risk of later being diagnosed with prostate cancer.

Higher cholesterol levels increase aggressive prostate cancer risk.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.